December 13, 2021

Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%.1 Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.2

TREATMENT GOALS — Establishing specific goals before starting...  Continue reading

More from Issue 1639
Previous Issue: 1638      November 29, 2021
Coming Soon
Antiviral Drugs for Influenza for 2021-2022
Molnupiravir - An Oral Antiviral Drug for COVID-19
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
Drugs for Acute Otitis Media in Children
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one. Booster doses of these vaccines were previously ... Continue reading